Sponsor:
AbbVie
Code:
NCT07728188
Conditions
Relapsed or Refractory Multiple Myeloma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Etentamig
Pomalidomide
Daratumumab
Dexamethasone
Carfilzomib
Brief summary:
Conditions
Relapsed or Refractory Multiple Myeloma
Study ID
NCT07728188
Start date
Oct 20, 2026
Status verified date
Nov, 2026
Completion date
Feb, 2033
Anticipated
Primary completion date
Feb, 2033
Anticipated
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Enrollment
520 participants
Anticipated
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary purpose
Treatment
Arms
experimental: Safety Run-In: Etentamig Plus Pomalidomide
experimental: Randomized Portion: Etentamig Plus Pomalidomide
active comparator: Randomized Portion: Standard Available Therapy (SAT)
Interventions
Etentamig
Pomalidomide
Daratumumab
Dexamethasone
Carfilzomib
Teclistamab
Primary outcome measure
Central contacts
Locations
Community Cancer Trials Of Utah /ID# 286936
Recruiting
Ogden, Utah, United States, 84405
Sponsor
AbbVie
Last update posted
Nov 17, 2026
Last verified
Nov, 2026
Keywords
Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-18. This information was provided to ClinicalTrials.gov by AbbVie on 2026-11-17. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.